Luke Nathaniel Walker
CIK 1701440 · Chief Medical Officer · last filed 2025-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$541.1K
Companies
4
Total Filings
14
Lifetime Open-Market Net
$25.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZNTL | Director | 144,284 | $3.75 | $541.1K | $25.0K | 3 | 2025-06-18 |
| CNTX | Director | — | $1.39 | — | $0 | 2 | 2025-06-12 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Chief Medical Officer | 0 | $23.01 | $0 | $0 | 5 | 2024-03-11 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | SVP, Clinical Development | 5,303 | — | — | $0 | 3 | 2018-02-02 |
Recent Filings · Page 2 of 2
14 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-13 | — | Mixed | −10,315 | $0 | |
| 2018-02-02 | Cascadian Therapeutics, Inc. (CASC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-16 | Cascadian Therapeutics, Inc. (CASC) Delisted | Mixed | +1,313 | -$2.5K | EDGAR |
| 2017-09-20 | Cascadian Therapeutics, Inc. (CASC) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 11–14 of 14
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.